Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Subestudo 03B: Um estudo de terapias combinadas imunológicas e direcionadas em participantes com carcinoma de células renais de segunda linha Plus (2L+) (MK-3475-03B)

23 de setembro de 2026 atualizado por: Merck Sharp & Dohme LLC

Um estudo de fase 1b/2 de terapias imunológicas e combinadas direcionadas em participantes com RCC (U03): Subestudo 03B

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).

The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC).

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

263

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New South Wales
      • Blacktown, New South Wales, Austrália, 2148
        • Blacktown Hospital ( Site 3601)
      • Kogarah, New South Wales, Austrália, 2217
        • St George Hospital ( Site 3602)
    • Queensland
      • Herston, Queensland, Austrália, 4029
        • Royal Brisbane and Women's Hospital ( Site 3603)
    • Victoria
      • Melbourne, Victoria, Austrália, 3084
        • Austin Health ( Site 3600)
    • Ontario
      • Toronto, Ontario, Canadá, M5G 1Z5
        • Princess Margaret Cancer Centre ( Site 3101)
    • Quebec
      • Montreal, Quebec, Canadá, H3T 1E2
        • Jewish General Hospital ( Site 3100)
    • Araucania
      • Temuco, Araucania, Chile, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 4108)
      • Temuco, Araucania, Chile, 4810148
        • CIDO SpA-Oncology ( Site 4106)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7500921
        • FALP-UIDO ( Site 4100)
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 4101)
    • Valparaiso
      • Viña del Mar, Valparaiso, Chile, 2520598
        • ONCOCENTRO APYS-ACEREY ( Site 4103)
      • Seoul, Coréia do Sul, 03722
        • Severance Hospital ( Site 3802)
      • Seoul, Coréia do Sul, 06351
        • Samsung Medical Center ( Site 3801)
    • Seoul
      • Songpagu, Seoul, Coréia do Sul, 05505
        • Asan Medical Center ( Site 3800)
      • Madrid, Espanha, 28034
        • Hospital Universitario Ramon y Cajal ( Site 3301)
    • Catalonia
      • Barcelona, Catalonia, Espanha, 08035
        • Hospital Universitari Vall d Hebron ( Site 3300)
    • California
      • San Francisco, California, Estados Unidos, 94158
        • University of California at San Francisco ( Site 3008)
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago ( Site 3013)
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa ( Site 3012)
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Health System ( Site 3014)
    • New York
      • New York, New York, Estados Unidos, 10016
        • Laura and Isaac Perlmutter Cancer Center ( Site 3016)
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 3002)
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke Cancer Institute ( Site 3015)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Cancer Center/Hillman Cancer Center ( Site 3017)
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University Medical Center ( Site 3004)
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UTSW Medical Center ( Site 3003)
    • Ain
      • Vandœuvre-lès-Nancy, Ain, França, 54519
        • Institut De Cancerologie De Lorraine ( Site 3204)
    • Alsace
      • Strasbourg, Alsace, França, 67200
        • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, França, 31059
        • Institut Claudius Regaud ( Site 3200)
    • Île-de-France Region
      • Villejuif, Île-de-France Region, França, 94800
        • Gustave Roussy ( Site 3202)
    • North Holland
      • Amsterdam, North Holland, Holanda, 1066 CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)
    • South Holland
      • Rotterdam, South Holland, Holanda, 3015 GD
        • Erasmus Medisch Centrum ( Site 4401)
    • Pest County
      • Budapest, Pest County, Hungria, 1122
        • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus-Oncology Division ( Site 3500)
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center-Oncology ( Site 3504)
      • Petah Tikva, Israel, 4941492
        • Rabin Medical Center ( Site 3502)
      • Ramat Gan, Israel, 52621
        • Sheba Medical Center - Oncology Division ( Site 3501)
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center ( Site 3503)
      • Auckland, Nova Zelândia, 1023
        • Auckland City Hospital ( Site 3700)
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polônia, 85-796
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polônia, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polônia, 80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)
      • Manchester, Reino Unido, M20 4BX
        • The Christie NHS Foundation Trust ( Site 3400)
    • England
      • Southampton, England, Reino Unido, SO16 6YD
        • Southampton General Hospital ( Site 3403)
    • Glasgow City
      • Glasgow, Glasgow City, Reino Unido, G12 0YN
        • The Beatson West of Scotland Cancer Centre ( Site 3405)
    • Lancashire
      • Preston, Lancashire, Reino Unido, PR2 9HT
        • Royal Preston Hospital ( Site 3406)
    • Leicestershire
      • Leicester, Leicestershire, Reino Unido, LE1 5WW
        • Leicester Royal Infirmary ( Site 3408)
    • London, City of
      • London, London, City of, Reino Unido, EC1A 7BE
        • Barts Health NHS Trust ( Site 3401)
    • Midlothian
      • Edinburgh, Midlothian, Reino Unido, EH4 2XU
        • Western General Hospital ( Site 3402)
    • Wales
      • Cardiff, Wales, Reino Unido, CF14 2TL
        • Velindre Cancer Centre Hospital ( Site 3407)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Has a histologically confirmed diagnosis of locally advanced/metastatic clear cell renal cell carcinoma (ccRCC)
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a programmed cell death ligand 1 (PD-(L)1) checkpoint inhibitor (in sequence or in combination with a vascular endothelial growth factor. - tyrosine kinase inhibitor [VEGF-TKI]) where PD-(L)1 checkpoint inhibitor treatment progression is defined by meeting ALL of the following criteria: (a) has received ≥2 doses of an anti-PD-(L)1 monoclonal antibody (mAb) (b) has shown radiographic disease progression during or after an anti-PD-(L)1 mAb as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by investigator (c) disease progression has been documented within 12 weeks from the last dose of an anti-PD-(L)1 mAb
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a VEGF-TKI (in sequence or in combination with a PD-[L]1 checkpoint inhibitor) where VEGF-TKI treatment progression is defined by meeting the following criterion: has shown radiographic disease progression during or after a treatment with a VEGF-TKI as defined by RECIST 1.1 by investigator.
  • Is able to swallow oral medication
  • Has adequate organ function
  • Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation
  • Has resolution of toxic effects of prior therapy to ≤Grade 1
  • Has adequately controlled blood pressure (BP ≤150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation
  • Male participants are abstinent from heterosexual intercourse or agree to use contraception during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or a combination of the aforementioned drugs, no contraception is needed
  • Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last and must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention

Exclusion Criteria:

  • Has urine protein ≥1 g/24 hours and has any of the following: (a) a pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen (d) active hemoptysis within 3 weeks prior to the first dose of study intervention
  • Has clinically significant cardiovascular disease within 12 months from the first dose of study intervention administration
  • Has had major surgery within 3 weeks before first dose of study interventions
  • Has a history of lung disease
  • Has a history of inflammatory bowel disease
  • Has preexisting gastrointestinal (GI) or non-GI fistula
  • Has malabsorption due to prior GI surgery or disease
  • Has previously received treatment with a combination of pembrolizumab plus lenvatinib
  • Has received prior treatment with belzutifan
  • Has received prior radiotherapy within 2 weeks of start of study intervention
  • Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention; killed vaccines are allowed
  • Has received more than 4 previous systemic anticancer treatment regimens
  • Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known history of Hepatitis B
  • Has had an allogenic tissue/solid organ transplant

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Coformulation Pembrolizumab/Quavonlimab

Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).

Administered via IV infusion at a dose of 400 mg/25 mg Q6W

Outros nomes:
  • MK-1308A
Experimental: Coformulation Favezelimab/Pembrolizumab

Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).

Administered via IV infusion at a dose of 800 mg/200 mg Q3W

Outros nomes:
  • MK-4280A
Experimental: Pembrolizumab + MK-4830

Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Outros nomes:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion at a dose of 800 mg Q3W

Experimental: Pembrolizumab + Belzutifan

Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.

Administered via oral tablet at a dose of 120 mg QD

Outros nomes:
  • MK-6482
  • WELIREG™

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Outros nomes:
  • MK-3475
  • KEYTRUDA®
Experimental: Belzutifan + Lenvatinib

Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.

Administered via oral capsule at a dose of 20 mg QD

Outros nomes:
  • E7080
  • MK-7902
  • LENVIMA®

Administered via oral tablet at a dose of 120 mg QD

Outros nomes:
  • MK-6482
  • WELIREG™
Experimental: Pembrolizumab + Lenvatinib

Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.

Administered via oral capsule at a dose of 20 mg QD

Outros nomes:
  • E7080
  • MK-7902
  • LENVIMA®

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Outros nomes:
  • MK-3475
  • KEYTRUDA®

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
Prazo: Up to ~21 days

DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting >7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for >1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for >14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the safety lead-in phase will be presented.

Up to ~21 days
Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
Prazo: Up to ~21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the safety lead-in phase will be presented.

Up to ~21 days
Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
Prazo: Up to ~21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the safety lead-in phase will be presented.

Up to ~21 days
Efficacy Phase: Number of participants who experienced DLTs
Prazo: Up to ~21 days

DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting >7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for >1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for >14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the efficacy phase will be presented.

Up to ~21 days
Efficacy Phase: Number of participants who experience one or more AEs
Prazo: Up to ~56 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the efficacy phase will be presented.

Up to ~56 months
Efficacy Phase: Number of participants who discontinue study treatment due to an AE
Prazo: Up to ~56 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the efficacy phase will be presented.

Up to ~56 months
Efficacy Phase: Objective response rate (ORR)
Prazo: Up to ~56 months

ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Up to ~56 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Efficacy Phase: Duration of response (DOR)
Prazo: Up to ~56 months

For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1.

Up to ~56 months
Efficacy Phase: Progression-free survival (PFS)
Prazo: Up to ~56 months

PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 by BICR.

Up to ~56 months
Efficacy Phase: Overall survival (OS)
Prazo: Up to ~56 months

OS is defined as the time from randomization to death due to any cause.

Up to ~56 months
Efficacy Phase: Clinical benefit rate (CBR)
Prazo: Up to ~56 months

CBR is defined as the percentage of participants who have achieved CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease) of ≥6 months. Responses are according to RECIST 1.1 by BICR.

Up to ~56 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de dezembro de 2020

Conclusão Primária (Real)

23 de julho de 2026

Conclusão do estudo (Real)

23 de julho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2020

Primeira postagem (Real)

12 de novembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

23 de setembro de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 3475-03B
  • MK-3475-03B (Outro identificador: MSD)
  • 2019-003610-13 (Número EudraCT)
  • KEYMAKER-U03 (Outro identificador: MSD)
  • U1111-1294-4557 (Identificador de registro: UTN)
  • 2023-506839-15-00 (Identificador de registro: EU CT)
  • 2023 (Concessão/Contrato do NIH dos EUA)
  • 2019 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever